Publication: Fractionated stereotactic radiotherapy for bilateral vestibular schwannomas associated with neurofibromatosis type 2: Early experiences in Ramathibodi Hospital
Issued Date
2004-09-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-5444260752
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.87, No.9 (2004), 1076-1081
Suggested Citation
Mantana Dhanachai, Veerasak Theerapancharoen, Jiraporn Laothamatas, Chanchai Jariengprasert, Puangtong Kraiphibul, Pornpan Yongvithisatid Fractionated stereotactic radiotherapy for bilateral vestibular schwannomas associated with neurofibromatosis type 2: Early experiences in Ramathibodi Hospital. Journal of the Medical Association of Thailand. Vol.87, No.9 (2004), 1076-1081. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/21546
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Fractionated stereotactic radiotherapy for bilateral vestibular schwannomas associated with neurofibromatosis type 2: Early experiences in Ramathibodi Hospital
Other Contributor(s)
Abstract
Purpose: To evaluate the rates of tumor control and useful hearing preservation in patients with bilateral vestibular schwannomas (VSs) associated with neurofibromatosis type 2 (NF-2) treated with fractionated stereotactic radiotherapy (FSRT). Material and Method: From August 1998-December 2002 there were 5 patients with NF-2 who underwent FSRT (Linac-based system) for bilateral CP angle tumors. Median age was 28 (18-47) years. Median tumor volume was 5.4 (2.2-9.4) cc. Eight lesions received a marginal dose of 44.2-59.9 (median = 46.2) Gy in 25-33 fractions. The other 2 lesions received 4.4 and 4.9 Gy/fraction for 6 fractions in 3 and 2 weeks. Median follow-up was 19 (14-44) months. Results: Radiographic and clinical tumor control rate was 90%. One lesion progressed at 7 months after FSRT and was completely resected. Of the 5 lesions with Gardner-Roberts on class I-II hearing before FSRT, 2 (40%) retained useful hearing at the last follow-up. One patient had left facial spasm at 10 months after FSRT which gradually improved. No patient had facial palsy, facial numbness or pain. Conclusions: FSRT provided good tumor control and hearing preservation rate in NF-2 patients with minimal morbidity. However, a longer follow-up is needed to evaluate long term results.